详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients

45| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Pharmacology and Physiology, The George Washington University, Washington, DC, USA [2]Department of Neurology, The George Washington University, Washington, DC, USA [3]Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China [4]Myasthenia Gravis Center and Department of Neurology, Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong, China

出处：

DOI：

ISSN：

关键词： Myasthenia gravis Autoimmune diseases Interleukin-17A

摘要：

To better define the role of IL-17A in myasthenia gravis (MG), we assessed plasma concentrations in 69 adult patients with MG prior to initiation of immunosuppression and monitored their clinical course for the subsequent 2 years with quantitative MG scores (QMGS) and Osserman classification. IL-17A was higher among patients than healthy control subjects. Early-onset women without thymoma had greater elevations of IL-17A. Logistic regression analysis indicated that the absence of thymoma rather than women gender or early-onset was the significant determinant associated with IL-17A elevation. Elevated IL-17A levels were associated with more severe MG. In summary, IL-17A has role in the pathogenesis of a subgroup of patients with early-onset women with MG with greater disease severity who are most likely to have thymic hyperplasia. This subgroup may be a target for IL-17 treatments, which are under development. (C) 2015 Elsevier Ltd. All rights reserved.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2015]版：

大类 | 3 区医学

小类 | 4 区生化与分子生物学 4 区细胞生物学 4 区免疫学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区生化与分子生物学 3 区细胞生物学 3 区免疫学

JCR分区：

出版当年[2014]版：

Q3 CELL BIOLOGY Q3 IMMUNOLOGY Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

最新[2023]版：

Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Q2 CELL BIOLOGY Q2 IMMUNOLOGY

影响因子： 最新[2023版] 3.7 最新五年平均[2021-2025] 3.5 出版当年[2014版] 2.664 出版当年五年平均[2010-2014] 2.717 出版前一年[2013版] 2.874 出版后一年[2015版] 2.94

第一作者：

第一作者单位： [2]Department of Neurology, The George Washington University, Washington, DC, USA [3]Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

通讯作者：

通讯机构： [1]Department of Pharmacology and Physiology, The George Washington University, Washington, DC, USA [2]Department of Neurology, The George Washington University, Washington, DC, USA [*1]Department of Pharmacology and Physiology, The George Washington University, 2300 I St NW, Washington, DC 20037, USA.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Recommendations for myasthenia gravis clinical trials [2]Advances in autoimmune myasthenia gravis management [3]Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients [4]Improved Accuracy in Myasthenia Gravis Using Combinatorial Algorithmic Autoantibody Testing [5]Revised Assessment Criteria for Prostigmine Test of Myasthenia Gravis [6]Different characteristics of nonthymomatous generalized myasthenia gravis with and without oropharyngeal involvement [7]Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China [8]Targeting FSTL1 for Multiple Fibrotic and Systemic Autoimmune Diseases [9]Potential medicinal value of m6A in autoimmune diseases and tumours [10]The Dynamic Interplay between the Gut Microbiota and Autoimmune Diseases